Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06801015
PHASE4

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after stopping the medication, and accommodation and satiation at 24 weeks compared to baseline.

Official title: A Randomized, Placebo-Controlled Trial of the Effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastric Motor Functions

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-10-01

Completion Date

2028-03-31

Last Updated

2025-12-26

Healthy Volunteers

No

Conditions

Interventions

DRUG

Semaglutide

Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week

DRUG

Tirzepatide

Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week

DRUG

Placebo

Placebo administered by subcutaneous injection once per week.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States